Age-related macular degeneration is a bilateral ocular condition in which the central area of the retina, known as the macula, is affected. Age-related macular degeneration is a progressive condition, and it is common among the geriatric population. The growing geriatric population is contributing to the rising incidence of age-related macular degeneration globally. As a result, there is a high demand for therapeutics to treat the condition. Pharmaceutical companies are leveraging this opportunity and are focusing on releasing drugs to treat age-related macular degeneration. Market Analysis and Insights: Global Age-Related Macular Degeneration (AMD) Therapeutics Market The global Age-Related Macular Degeneration (AMD) Therapeutics market size is projected to reach US$ XX million by 2027, from US$ XX million in 2020, at a CAGR of XX% during 2021-2027. With industry-standard accuracy in analysis and high data integrity, the report makes a brilliant attempt to unveil key opportunities available in the global Age-Related Macular Degeneration (AMD) Therapeutics market to help players in achieving a strong market position. Buyers of the report can access verified and reliable market forecasts, including those for the overall size of the global Age-Related Macular Degeneration (AMD) Therapeutics market in terms of revenue. On the whole, the report proves to be an effective tool that players can use to gain a competitive edge over their competitors and ensure lasting success in the global Age-Related Macular Degeneration (AMD) Therapeutics market. All of the findings, data, and information provided in the report are validated and revalidated with the help of trustworthy sources. The analysts who have authored the report took a unique and industry-best research and analysis approach for an in-depth study of the global Age-Related Macular Degeneration (AMD) Therapeutics market. Global Age-Related Macular Degeneration (AMD) Therapeutics Scope and Market Size Age-Related Macular Degeneration (AMD) Therapeutics market is segmented by company, region (country), by Type, and by Application. Players, stakeholders, and other participants in the global Age-Related Macular Degeneration (AMD) Therapeutics market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by Type and by Application in terms of revenue and forecast for the period 2016-2027. Segment by Type Wet AMD Dry AMD Segment by Application Hospital Clinic Research Institute Other By Region North America U.S. Canada Europe Germany France U.K. Italy Russia Nordic Rest of Europe Asia-Pacific China Japan South Korea Southeast Asia India Australia Rest of Asia Latin America Mexico Brazil Rest of Latin America Middle East & Africa Turkey Saudi Arabia UAE Rest of MEA By Company Amgen Inc. Bausch Health Companies, Inc. F. Hoffmann-La Roche Ltd. Novartis AG Regeneron Pharmaceuticals Inc.
1 Report Overview 1.1 Study Scope 1.2 Market Analysis by Type 1.2.1 Global Age-Related Macular Degeneration (AMD) Therapeutics Market Size Growth Rate by Type: 2016 VS 2021 VS 2027 1.2.2 Wet AMD 1.2.3 Dry AMD 1.3 Market by Application 1.3.1 Global Age-Related Macular Degeneration (AMD) Therapeutics Market Share by Application: 2016 VS 2021 VS 2027
